肠道微生物组调节了接受化疗的初级中枢神经系统淋巴瘤患者的结果:来自BLOCAGE试验的辅助研究
Isaias Hernández-Verdin1, Eva Kirasic1, Karima Mokhtari1,2
1Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, F-75013 Paris, France.
Neuro-oncology
|March 6, 2025
概括
肠道细菌的组成会影响初级中枢神经系统淋巴瘤 (PCNSL) 的治疗结果. 较高的Parabacteroides distasonis水平与更好的生存率相关,这表明个性化治疗策略的潜力.
科学领域:
- 在瘤学瘤学.
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 主要中枢神经系统淋巴瘤 (PCNSL) 治疗通常涉及高剂量甲状腺基化疗 (HD-MTX 基CT).
- 肠道微生物群组成与PCNSL治疗反应之间的关联尚未完全理解.
研究的目的:
- 调查接受标准治疗的PCNSL患者肠道微生物群组成和临床结果之间的关系.
- 探索潜在的生物标志物来预测治疗反应和指导个性化治疗策略.
主要方法:
- 对PCNSL患者 (NCT02313389,NCT04253496) 进行前性研究,这些患者接受了一线基于HD-MTX的多化学疗法.
- 采集和分析便,脑脊液 (CSF) 和血样本,使用metagenomic,流细胞计和代谢学技术.
- 验证队列使用来自BLOCAGE临床试验 (NCT04253496) 的血代谢学数据.
主要成果:
- 确定了两个不同的肠道微生物群落,通过Parabacteroides distasonis丰富度进行区分.
- 较高的P. distasonis水平与改善的无进展和整体存活率有显著的相关性.
- 升高的P. distasonis与血贝他因/氨酸代谢物增加和CSF CD8 T细胞透增加有关,这表明免疫调节.
结论:
- 肠道微生物组的组成会影响接受标准化疗的PCNSL患者的临床结果.
- 帕拉巴克泰罗伊德 (Parabacteroides distasonis) 的丰富程度可以作为患者分层的预测生物标志物.
- 测量P. distasonis的数量可以在未来为PCNSL提供个性化治疗策略.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Gut-Brain Axis
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...


